About
Optogenetic therapy that works regardless of the underlying RP mutation. Rolling BLA submission to the FDA began Jul 2025; first modules submitted, completion anticipated early 2026.
HQ: Dallas, TX, USA
Funding
Funding data unverified (trackers show stale $12.8M Series B)
Do not treat as latest; BLA filing effort implies more recent activity.